Development Of A High-Dose Engineered Tcr T Cell Manufacturing Process Using Automated Semi-Continuous Perfusion Bioreactors
January 15-19, 2017
Clinical activity with engineered TCR (eTCR) T cell products directed against solid tumor indications may require doses up to two orders of magnitude greater than those investigated during CAR-T studies in hematological malignancies.1 Novel methods for optimizing productivity and production times are required to progress the industrial feasibility of high-dose cell therapies. We developed an automated semi-continuous perfusion culture method suitable for rapidly generating high T cell densities with the aid of risk-based process models. The result is a robust manufacturing process capable of generating a target dose with high certainty, and minimal operational complexity and variability.
Please click Additional Files below to see the full abstract.
Kenny Choi, Jacob Okhovat, Marianna Sabatino, and Marc Better, "Development Of A High-Dose Engineered Tcr T Cell Manufacturing Process Using Automated Semi-Continuous Perfusion Bioreactors" in "Scale-up and Manufacturing of Cell-based Therapies V", Tom Brieva, Celgene Cellular Therapeutics William Miller, Northwestern University Chris Mason, University College London Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/cellbasedtherapies_v/109
This document is currently not available here.